Bronchial asthma and cardiovascular comorbidity: interconnections and approaches to therapy


DOI: https://dx.doi.org/10.18565/therapy.2022.5.62-66

Starodubtseva I.A., Lesina V.S., Kostina N.E., Venderevskaya K.V.

1) N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia; 2) Voronezh Regional Clinical Hospital No. 1
Abstract. The article deals with the problem of cardiovascular comorbidity in patients with bronchial asthma. In addition to the chronic inflammatory process as a risk factor for the development of cardiovascular diseases, special attention is paid to the effect of disease-control therapy. Recent data even demonstrate common genetic background for the coexistence of the two diseases. In this regard, it is important not only to detect cardiovascular pathology at an early stage, but also to take into account concomitant conditions when choosing the basic therapy for the underlying disease. According to the latest data, the use of bioengineering therapy in the treatment of patients with severe bronchial asthma is justified from the standpoint of not only effectiveness against the underlying disease, but also cardioprotective action.
Keywords: biological agents, comorbidity, bronchial asthma, cardiovascular diseases
Read entire article

Literature

1. Reddel H.K., Bacharier L.B., Bateman E.D. et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021; 59(1): 2102730. https://dx.doi.org/10.1183/13993003.02730-2021.


2. Zinellu E., Piras B., Ruzittu G. et al. Recent advances in inflammation and treatment of small airways in asthma. Int J Mol Sci. 2019; 20(11): 2617. https://dx.doi.org/10.3390/ijms20112617.


3. Hamid Q, Tulic’ M.K., Liu M.C., Moqbel R. Inflammatory cells in asthma: mechanisms and implications for therapy. J Allergy Clin Immunol. 2003; 111(1 Suppl): S5–S12; discussion S12–17. https://dx.doi.org/10.1067/mai.2003.22.


4. Bogos K., Ostoros G. COPD. Koranyi Bulletin. 2019. URL: https://szakmai.koranyi.hu/bulletin (date of access – 12.02.2021).


5. Weatherburn C.J., Guthrie B., Mercer S.W., Morales D.R. Comorbidities in adults with asthma: population-based cross-sectional analysis of 1.4 million adults in Scotland. Clin Exp Allergy. 2017; 47(10): 1246–52. https://dx.doi.org/10.1111/cea.12971.


6. Kaplan A., Szefler S.J., Halpin D.M.G. Impact of comorbid conditions on asthmatic adults and children. NPJ Prim Care Respir Med. 2020; 30(1): 36. https://dx.doi.org/10.1038/s41533-020-00194-9.


7. Boulet L.-P. Influence of comorbid conditions on asthma. Eur Respir J. 2009; 33(4): 897–906. https://dx.doi.org/10.1183/09031936.00121308.


8. Boulet L.-P., Boulay M.-E. Asthma-related comorbidities. Expert Rev Respir Med. 2011; 5(3): 377–93.https://dx.doi.org/10.1586/ers.11.34.


9. Ledford D.K., Lockey R.F. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013; 13(1): 78–86.https://dx.doi.org/10.1097/ACI.0b013e32835c16b6.


10. Авдеев С.Н., Ненашева Н.М., Жуденков К.В. с соавт. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации. Пульмонология. 2018; 3: 341–358. [Avdeev S.N., Nenasheva N.M., Zhudenkov K.V. et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya = Pulmonology. 2018; 3: 341–358 (In Russ.)].https://dx.doi.org/10.18093/0869-0189-2018-28-3-341-358. EDN: XWCRRZ.


11. Ненашева Н.М. Омализумаб в терапии тяжелой бронхиальной астмы. Эффективная фармакотерапия. 2014; 29: 24–35. [Nenasheva N.M. Omalizumab in therapy of severe bronchial asthma. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2014; 29: 24–35 (In Russ.)]. EDN: SXVCNH.


12. Федеральные рекомендации по диагностике и лечению бронхиальной астмы. Российское респираторное общество. 2016. Доступ: http://spulmo.ru/obshchestvo/news/news-812/ (дата обращения – 15.06.2022). [Federal guidelines for the diagnosis and treatment of bronchial asthma. Russian Respiratory Society. 2016.URL: http://spulmo.ru/obshchestvo/news/news-812/ (date of access – 15.06.2022) (In Russ.)].


13. Гринберг Н.Б., Воронина Л.П., Полунина О.С. с соавт. Функциональное состояние сосудистого эндотелия и его влияние на ремоделирование миокарда у больных бронхиальной астмой. Астраханский медицинский журнал. 2012; 2: 58–61. [Grinberg N.B., Voronina L.P., Polunina O.S. et al. The functional status of vascular endothelium and its influence on remodeling of myocardium of patients with bronchial asthma. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal. 2012; 2: 58–61 (In Russ.)]. EDN: PAXTVB.


14. Schanen J.G., Iribarren C., Schanen J.G. et al. Asthma and incident cardiovascular disease: The atherosclerosis risk in communities study. Thorax. 2005; 60(8): 633–38. https://dx.doi.org/10.1136/thx.2004.026484.


15. Ненашева Н.М. Биологическая терапия бронхиальной астмы: настоящее и будущее. Consilium Medicum. 2016; 11: 30–38. [Nenasheva N.M. Biological therapy of asthma: present and future. Consilium Medicum. 2016; 11: 30–38 (In Russ.)]. EDN: YGILVT.


16. Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011; 6: 87–93. [Arkhipov V.V., Grigoryeva E.V., Gavrishina E.V. Control of bronchial asthma in Russia: results of NIKA multi-center observational study. Pulmonologiya = Pulmonology. 2011; 6: 87–93 (In Russ.)]. https://dx.doi.org/10.18093/0869-0189-2011-0-6-87-93. EDN: RCMQNO.


17. Grow from Knowledge (GFK). Изучение поведения врачей при лечении пациентов с бронхиальной астмой (БА) и хронической обструктивной болезнью легких (ХОБЛ). 2018. Доступ: https://www.gfk.com/fileadmin/user_upload/dyna_content/RU/Documents/News/2015/Out-patient-treatment-ofbronchial-asthma-current-clinical-practice-review.doc (дата обращения – 26.06.18). [The study of the behavior of doctors in the treatment of patients with bronchial asthma and COPD. 2018. URL: https://www.gfk.com/fileadmin/user_upload/dyna_content/RU/Documents/News/2015/Out-patient-treatment-ofbronchial-asthma-current-clinical-practice-review.doc (date of access – 26.06.18) (In Russ.)].


18. Харитонс М.А., Рамазанова К.А. Современные представления о лечении бронхиальной астмы. Терра Медика Нова. 2001; 1: 22–24. [Kharitons M.A., Ramazanova K.A. Modern ideas about the treatment of bronchial asthma. Terra Medica Nova. 2001; 1: 22–24 (In Russ.)].


19. Сергеева Г.Р., Емельянов А.В., Коровина О.В. с соавт. Тяжелая бронхиальная астма: характеристика пациентов в клинической практике. Терапевтический архив. 2015; 12: 26–31. [Sergeeva G.R., Emelyanov A.V., Korovina O.V. et al. Severe asthma: characteristics of patients in clinical practice. Terapevticheskiy arkhiv = Therapeutic Archive. 2015; 12: 26–31 (In Russ.)].https://dx.doi.org/10.17116/terarkh2015871226-31. EDN: VKWGNH.


20. Рудакова А.В. Фармакоэкономические аспекты поддерживающей терапии бронхиальной астмы ингаляционными кортикостероидами. Качественная клиническая практика. 2013; 1: 47–49. [Rudakova A.V. Pharmacoeconomic aspects of maintenance therapy of bronchial asthma with inhaled corticosteroids. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2013; 1: 47–49(In Russ.)]. EDN: RWVPCR.


21. Gorecka D. Cardiac arrhythmias in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 1997; 52(3): 278–81.


22. Sbarbaro G., Parentini G.C., Angelinelli P.L. et al. [Respiratory insufficiency and cardiac arrhythmia: the rationale of treatment. Minerva Med. 1993; 84(6): 307–12 (in Italian)].


23. Takemura M., Matsumoto H., Niimi A. et al. High sensitivity C-reactive protein in asthma. Eur Respir J. 2006; 27(5): 908–12.https://dx.doi.org/10.1183/09031936.06.00114405.


24. Yokoyama A., Kohno N., Fujino S. et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med. 1995; 151(5): 1354–58. https://dx.doi.org/10.1164/ajrccm.151.5.7735584.


25. Aviles R.J., Martin D.O., Apperson-Hansen C. et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108(24): 3006–10. https://dx.doi.org/10.1161/01.CIR.0000103131.70301.4F.


26. Schnabel R.B., Larson M.G., Yamamoto J.F. et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010; 121(2): 200–7. https://dx.doi.org/10.1161/CIRCULATIONAHA.109.882241.


27. Adimadhyam S., Schumock G.T., Walton S. et al. Risk of arrhythmias associated with ipratropium bromide in children, adolescents, and young adults with asthma: A nested case-control study. Pharmacotherapy. 2014; 34(4): 315–23. https://dx.doi.org/10.1002/phar.1336.


28. Sears M.R. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002; 110(6 Suppl): S322–28. https://dx.doi.org 10.1067/mai.2002.129966.


29. Cazzola M., Matera M.G., Donner C.F. Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs. 2005; 65(12): 1595–610. https://dx.doi.org/10.2165/00003495-200565120-00001.


30. Robin E.D., McCauley R. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. Chest. 1992; 101(6): 1699–702. https://dx.doi.org/10.1378/chest.101.6.1699.


31. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004: 125(6): 2309–21. https://dx.doi.org/10.1378/chest.125.6.2309.


32. Mohammad H.A., Abdulfttah M.T., Abdulazez A.O. et al. A study of electrolyte disturbances in patients with chronic stable asthma and with asthma attacks. Egypt J Chest Dis Tuberc. 2014; 63(3): 529–34.


33. Cazzola M., Rogliani P., Calzetta L., Matera M.G. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019; 151: 43–48. https://dx.doi.org/10.1016/j.rmed.2019.04.001.


34. Crane J., Burgess C.D., Graham A.N., Maling T.J. Hypokalaemic and electrocardiographic effects of aminophylline and salbutamol in obstructive airways disease. N Z Med J. 1987; 100(824): 309–11.


35. Maak C.A., Tabas J.A., McClintock D.E. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med. 2011; 40(2): 135–45. https://dx.doi.org/10.1016/j.jemermed.2007.11.056.


36. Gulsen A. Asthma phenotypes and current biological treatments. In book: Asthma [Working Title]. April 2021.}https://dx.doi.org/10.5772/intechopen.97376.


About the Autors

Irina A. Starodubtseva, Dr. med. habil., associate professor of the Department of propaedeutics of internal diseases, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya Str. E-mail: starodubtsevairina1@gmail.com. ORCID: https://orcid.org/0000-0002-4665-2966
Victoria S. Lesina, a person attached to the Department of propaedeutics of internal diseases, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia, pulmonologist at the Department of pulmonology, Voronezh Regional Clinical Hospital No. 1. Address: 394066, Voronezh, 151 Moskovsky Avenue. ORCID: https://orcid.org/0000-0001-8231-6591
Natalya E. Kostina, PhD in Medicine, head of the Department of pulmonology, Voronezh Regional Clinical Hospital No. 1. Address: 394066, Voronezh, 151 Moskovsky Avenue. E-mail: nata166k@yahoo.com. ORCID: https://orcid.org/0000-0002-5128-5005
Kristina V. Venderevskaya, doctor of the Admission Department, Voronezh Regional Clinical Hospital No. 1. Address: 394066, Voronezh, 151 Moskovsky Avenue. ORCID: https://orcid.org/0000-0001-9652-8528


Similar Articles

Back to Content

Бионика Медиа